Antibiotic administration and the development of obesity in children

Nicola Principi1, Susanna Esposito1

  • 1Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda 9, 20122 Milan, Italy.

Insights

Antibiotic use in children can disrupt gut microbiota, increasing obesity risk. Further research is needed to understand and prevent this link, promoting judicious antibiotic prescribing.

Area of Science:

  • Pediatric Health
  • Microbiology
  • Metabolic Disorders

Background:

  • Antibiotics are frequently prescribed to children, leading to potential gut microbiota dysbiosis.
  • This dysbiosis is increasingly linked to childhood obesity, a risk factor for adult obesity and severe health issues.
  • Early-life dysbiosis significantly impacts immune system development and metabolic regulation.

Purpose of the Study:

  • To highlight the emerging issue of antibiotic-induced gut microbiota dysbiosis in pediatric patients.
  • To underscore the association between dysbiosis and the rising prevalence of childhood obesity.
  • To emphasize the need for further research into the mechanisms and therapeutic strategies for this condition.

Main Methods:

  • Review of current literature on antibiotic use, gut microbiota, and pediatric obesity.
  • Analysis of the impact of early-life dysbiosis on immune and metabolic development.
  • Exploration of potential therapeutic roles for probiotics and prebiotics.

Main Results:

  • Antibiotic administration in children can lead to gut microbiota alterations.
  • These alterations are associated with an increased risk of developing obesity.
  • The precise mechanisms linking dysbiosis to obesity require further elucidation.

Conclusions:

  • Antibiotic-induced gut dysbiosis is a significant concern in pediatric health, contributing to obesity.
  • Probiotics and prebiotics show potential in managing microbiota disruptions.
  • Judicious antibiotic use in children is crucial, necessitating further studies to break the link between antibiotics, dysbiosis, and obesity.

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
368
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
335
Antibiotic Selection00:57

Antibiotic Selection

Overview
62.0K
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
1.9K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
279
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
693